The Latest News from GenNext Technologies

GenNext Technologies Announces NIH Grant Funding of Nearly $7M Leads to a Seminal Protein Footprinting Patent

HALF MOON BAY, Calif.April 28, 2021Life Science Newswire  – GenNext Technologies, Inc., a growth-stage company that provides instrumentation, software, and services to structural biology researchers within the biopharmaceutical industry, announced today that nearly $7M (US) in NIH grant awards has led to a seminal US patent for its novel technology that vastly improves the utility of protein footprinting for the study of biopharmaceutical higher order structure.

GenNext Technologies is honored to have earned a total of nine National Institute of General Medical Sciences grant awards to support the development of their breakthrough Hydroxyl Radical Protein Footprinting (HRPF) instrumentation and data processing software, known as the Flash Oxidation (Fox™) Protein Footprinting System.

This powerful, compact, and cost-effective platform enables researchers to conduct reproducible HRPF experiments quickly, easily, and safely. The Fox™ System reveals important information about protein interactions and structural changes, leading to the development of safer and more effective biotherapeutics.

A GenNext HRPF study can answer scientific questions that previously required difficult,  expensive, and time-consuming nuclear magnetic resonance, X-ray crystallography or cryo-electron microscopy experiments. Alternatively, researchers would have to combine multiple techniques such as circular dichroism spectroscopy, size-exclusion chromatography, and light-scattering analysis to generate less informative results than running a single GenNext HRPF experiment.

In recognition of GenNext’s novel technology, the United States Patent and Trademark Office issued Patent US 10,816,468 B2 for “Flash Photo-Oxidation Device and Higher Order Structural Analysis.” This patent protects the company’s proprietary technology and knowhow that enable, for the first time, real-time assessment of photo-chemical reactions and provide robust reproducibility, while substantially improving ease-of-use.

The mission of GenNext is to help researchers quickly and easily elucidate the critical role that protein structure plays in the safety, stability, and biological function of biotherapeutics,” said Scot R. Weinberger, Founder and CEO of GenNext. “By integrating our novel instrumentation and data processing software into their structural biology workflow, our customers can answer key drug development questions in days rather than weeks or months. We look forward to helping our customers accelerate the development of safer and more effective drugs to improve human health.

GenNext’s new approach is described in a peer-reviewed article recently published in the Journal of the American Society for Mass Spectrometry, The Flash Oxidation (FOX) System: A Novel Laser-Free Fast Photochemical Oxidation Protein Footprinting Platform, authored by researchers from GlycoScientific, University of Mississippi, University of Georgia, and GenNext Technologies

Recently, GenNext teamed-up with its alliance partner, NeoProteomics, to produce a five-part seminar series on the science of protein footprinting including applications, methods development, techniques, and data analysis. The series was created and presented by structural biology luminaries who are also members of the GenNext Scientific Advisory Board: Professors Mark Chance (Case Western Reserve), Michael Gross (Washington University in St. Louis), Joshua Sharp (University of Mississippi), and Lisa Jones (University of Maryland). These seminars are available for on-demand viewing on the GenNext website.

For more information, please see our website at


About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our disruptive products and services are aimed at improving structural biology-focused research. Ultimately, we seek to help accelerate biopharmaceutical development, while improving therapeutic efficacy and safety.


Scot R. Weinberger
Founder and CEO
[email protected]


Companies team-up to promote the use of protein footprinting technologies, products, and contract research services in biopharmaceutical research and development.

Montara, California, June 16th, 2020 – GenNext Technologies (GenNext) and NeoProteomics (Neo) have joined forces to advance biomolecular footprinting know-how and utility in biopharmaceutical and structural biology research. Neo is a world-recognized leader in footprinting software and services for biopharmaceutical and structural biology research. GenNext is the world’s only provider of footprinting instruments, software, and accessories that enable higher order structural analysis in a compact, intuitively simple, benchtop format.

Together, both companies are developing an informative website,, dedicated to facilitating the rapid exchange of scholarly content and discourse among researchers working in pharmaceutical and biopharmaceutical development as well as structural biological studies. This website will also provide understandable application examples so scientists and decision makers in the field can immediately grasp the impact of protein footprinting upon their research.

As a next step in educating the community, the companies are pleased to announce an upcoming webinar series to disseminate footprinting know-how and highlight its applied value in biopharmaceutical and structural biology research. Five, one-hour information packed webinars are planned to be presented by leaders in the biomolecular footprinting field, including: Professor Mark Chance (Case Western Reserve University), Professor Michael Gross (Washington University, St. Louis), Professor Joshua Sharp (University of Mississippi), and Professor Lisa Jones (University of Maryland Baltimore). The first seminar is scheduled for September 23rd, 2020, with more information found at

“We are excited to launch this alliance with NeoProteomics,” remarked Scot Weinberger, President and CEO of GenNext Technologies. “In academic studies, footprinting has provided valuable information by exposing monoclonal antibody defects, elucidating biosimilar failure and storage induced defects, and facilitating the study of orthosteric and allosteric drug-target interactions and protein conformational change. Until now, footprinting has been scantly applied in biopharma due to the inherent complexities of the technique and the absence of facile and reliable commercial products. GenNext provides biopharmas with the world’s first dedicated instrumentation and software products for biopharmaceutical higher order structural studies, which exploit the analytical power of biomolecular footprinting.”

“We too are pleased to align with GenNext Technologies to launch and promote this educational platform.” said John Schenkel, Jr., President and CEO of NeoProteomics. “Over the past few years, we’ve worked with our biotechnology clients and collaborators to demonstrate that protein footprinting is a very precise and versatile biophysical technique, which provides highly significant and actionable data. What’s most exciting however, is the introduction of new technologies which make Protein Footprinting much more accessible. We feel very strongly that by utilizing Protein Footprinting, researchers will be better equipped to attack human disease.”

About GenNext Technologies Inc.

GenNext Technologies, Inc., is an early stage biotechnology services and instrumentation company located in the San Francisco Bay Area. The company is committed to the advancement of biopharmaceuticals by introducing revolutionary new solutions for protein higher order structural analysis. GenNext is developing disruptive technology and products to mature the technique of Hydroxyl Radical Protein Footprinting (HRPF), with the goals of accelerating biopharmaceutical development, reducing biopharmaceutical manufacturing cost, while improving biopharmaceutical patient efficacy and safety. The GenNext team is an accomplished collection of scientists and engineers who have been creating first-in-class life science tools for over thirty years.

About NeoProteomics Inc.

NeoProteomics, Inc. (Neo), is a Cleveland, Ohio based contract research organization, founded in 2006, by Mark Chance and John Schenkel, Jr. Neo’s team of world-class structural and pharmacological experts specialize in offering high-resolution protein structure characterization services to industrial laboratories looking to accelerate their discovery and drug development programs. Over the past ten years, Neo has been utilizing Protein Footprinting (HRPF) techniques to develop and expand services to help solve biotechnology’s most challenging structural questions including membrane proteins and GPCR’s. Neo services include: epitope – paratope mapping; protein – ligand binding; H2L- lead generation; and expert consulting. For more information, please see